Release of dopamine and 5-hydroxytryptamine from rat striatal slices following activation of nicotinic cholinergic receptors.
1. The administration of the nicotinic cholinergic agonists dimethylphenylpiperazinium iodide (DMPP) or nicotine caused a concentration dependent release of [3H] dopamine, [3H]5-hydroxytryptamine as well as endogenous dopamine and 5-hydroxytryptamine from superfused slices of rat striatum. 2. Release of both labelled and non-labelled transmitter was antagonized by the nicotinic antagonist, hexamethonium but not the muscarinic antagonist, atropine. 3. The present study provides additional evidence that nicotinic-cholinergic receptors are present in the mammalian central nervous system. 4. Activation of these nicotinic-cholinergic receptors in the striatum results in the release of both dopamine and 5-hydroxytryptamine.
D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism*; D004246:Dimethylphenylpiperazinium Iodide / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism*; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology; D007031:Hypothalamus / Q000378:metabolism; D066298:In Vitro Techniques; D008297:Male; D018377:Neurotransmitter Agents / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains; D011950:Receptors, Cholinergic / Q000378:metabolism*; D011978:Receptors, Nicotinic / Q000378:metabolism*; D012701:Serotonin / Q000378:metabolism*
D006584:Hexamethonium Compounds; D018377:Neurotransmitter Agents; D011950:Receptors, Cholinergic; D011978:Receptors, Nicotinic; D012701:Serotonin; D018738:Hexamethonium; D004246:Dimethylphenylpiperazinium Iodide; D004298:Dopamine